Bafetinib    INNO-406      CML    Chronic Myeloid Leukemia

  Bafetinib (formerly known as INNO-406) is a dual Bcr-Abl and Lyn-kinase inhibitor. Bafetinib was developed by the team at Kyoto University Hospital in collaboration with Nippon Shinyaku.
                   "Bafetinib was 25-55 times more potent than imatinib in blocking BCR/ABL autophosphorylation, while otherwise retaining specificity for ABL and Lyn. Bafetinib had antiproliferative effects against cells bearing wild-type or most mutated BCR/ABL proteins, except T315I, and also inhibited BCR/ABL-positive leukemic cell growth in the central nervous system." 
​Extract from Med-Chemist Paragraph.

ARTICLES

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
May 9, 2016, Nature

CytRx’s ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting
October 4, 2011, BusinessWire

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia
December 11, 2010, PublMed

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
June 2, 2010, Med-Chemist

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
June 1, 2010, PublMed